203 related articles for article (PubMed ID: 23140120)
1. Toward prediction of immune mechanisms and design of immunotherapies in melanoma.
Tsoka S; Ainali C; Karagiannis P; Josephs DH; Saul L; Nestle FO; Karagiannis SN
Crit Rev Biomed Eng; 2012; 40(4):279-94. PubMed ID: 23140120
[TBL] [Abstract][Full Text] [Related]
2. Introduction to the role of the immune system in melanoma.
Margolin K
Hematol Oncol Clin North Am; 2014 Jun; 28(3):537-58. PubMed ID: 24880946
[TBL] [Abstract][Full Text] [Related]
3. Next generation of immunotherapy for melanoma.
Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for melanoma: current status and perspectives.
Alexandrescu DT; Ichim TE; Riordan NH; Marincola FM; Di Nardo A; Kabigting FD; Dasanu CA
J Immunother; 2010; 33(6):570-90. PubMed ID: 20551839
[TBL] [Abstract][Full Text] [Related]
5. Dissecting tumor responsiveness to immunotherapy: the experience of peptide-based melanoma vaccines.
Mocellin S; Rossi CR; Nitti D; Lise M; Marincola FM
Biochim Biophys Acta; 2003 Dec; 1653(2):61-71. PubMed ID: 14643925
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory cytokines as therapeutic agents for melanoma.
Nicholas C; Lesinski GB
Immunotherapy; 2011 May; 3(5):673-90. PubMed ID: 21554095
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for advanced melanoma: Current knowledge and future directions.
Nakamura K; Okuyama R
J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for melanoma.
Cuevas LM; Daud AI
Semin Cutan Med Surg; 2018 Jun; 37(2):127-131. PubMed ID: 30040090
[TBL] [Abstract][Full Text] [Related]
9. Principles of Immunotherapy in Melanoma.
Onitilo AA; Wittig JA
Surg Clin North Am; 2020 Feb; 100(1):161-173. PubMed ID: 31753110
[TBL] [Abstract][Full Text] [Related]
10. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for cutaneous malignancy.
Ibrahim SF; Sambandan D; Ratner D
Dermatol Surg; 2011 Oct; 37(10):1377-93. PubMed ID: 21806705
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.
Lee N; Zakka LR; Mihm MC; Schatton T
Pathology; 2016 Feb; 48(2):177-87. PubMed ID: 27020390
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for the management of advanced melanoma: the next steps.
Zikich D; Schachter J; Besser MJ
Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma-The cradle of anti-neoplastic immunotherapy.
Koller KM; Wang W; Schell TD; Cozza EM; Kokolus KM; Neves RI; Mackley HB; Pameijer C; Leung A; Anderson B; Mallon CA; Robertson G; Drabick JJ
Crit Rev Oncol Hematol; 2016 Oct; 106():25-54. PubMed ID: 27637351
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic strategies for the treatment of malignant melanoma.
Alexeev V; Mucci T; Igoucheva O
G Ital Dermatol Venereol; 2008 Apr; 143(2):139-49. PubMed ID: 18833040
[TBL] [Abstract][Full Text] [Related]
16. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
17. Advances in specific immunotherapy of malignant melanoma.
Curiel-Lewandrowski C; Demierre MF
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):167-85; quiz 186-8. PubMed ID: 10906637
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of advanced or metastatic melanoma.
Cebon J; Gedye C; John T; Davis ID
Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
[TBL] [Abstract][Full Text] [Related]
19. [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].
Moura B; Homicsko K; Berthod G; Cerottini JP; Guggisberg D; Gaide O; Maillard MH; Michielin O
Rev Med Suisse; 2015 May; 11(475):1108, 1110-4. PubMed ID: 26152085
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy of melanoma].
Dréno B
Bull Acad Natl Med; 2010 Oct; 194(7):1373-81. PubMed ID: 22043632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
